



## Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications September 2019 CPT® Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its September 2019 meeting are listed below. These applications will be included in the proposed Panel agenda that will be posted to the AMA website on July 16, 2019. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full September Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X01T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31<sup>st</sup> of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31<sup>st</sup> of the corresponding year.**

Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a request for a copy of the application and associated materials to [Michael Pellegrino](#). This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

\*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form.

Updated July 16, 2019

- New
- ▲ Revision
- ⊕ Add on
- D Deletion

Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
<b>Request for Code Change Application Materials</b>	<b>July 29</b>
<b>Submission of Written Comments</b>	<b>August 5</b>

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the September 2019 meeting, which will be published on or before October 25, 2019 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

Tab #	Name	Code #	Request-Description
29	Tier 1-SF3B1, SRSF2, U2AF1, ZRSR2	<ul style="list-style-type: none"> <li>● 8XX00</li> <li>● 8XX01</li> <li>● 8XX02</li> <li>● 8XX03</li> </ul>	Add four Tier 1 codes for testing of SF3B1, SRSF2, U2AF1, and ZRSR2 genes.
30	Tier 1-NTRK	<ul style="list-style-type: none"> <li>● 8X000</li> <li>● 8X001</li> <li>● 8X002</li> </ul>	Add three Molecular Pathology Tier 1 codes (8X000, 8X001, 8X002) to report neurotrophic receptor tyrosine kinase.

Updated July 16, 2019

- New
- ▲ Revision
- + Add on
- D Deletion

Tab #	Name	Code #	Request-Description
31	S-Tier 1-SF3B1	<ul style="list-style-type: none"> <li>● 8XX04</li> <li>● 8XX05</li> </ul>	Add two Molecular Pathology Tier 1 codes for analysis of common variants of the SF3B1 gene (8XX04) and sequence analysis, exons 13-16 of the SF3B1 gene (8XX05).
32	S-Tier 2 to Tier 1-TP53	<ul style="list-style-type: none"> <li>● 8X003</li> <li>● 8X004</li> <li>● 8X005</li> <li>● 81405</li> <li>▲ 81406</li> </ul>	Revise codes 81405, 81406 by removing TP53 test 2 and adding three Tier 1 codes to report tumor protein 53.
33	S-Tier 2 to Tier 1-MPL	<ul style="list-style-type: none"> <li>● 8X006</li> <li>● 8X007</li> <li>▲ 81402</li> <li>▲ 81403</li> </ul>	Add two Tier 1 codes to report myeloproliferative disorder and remove these tests from codes 81402 and 81403.
34	S-Tier 2 to Tier 1-JAK2	<ul style="list-style-type: none"> <li>● 8X008</li> <li>▲ 81403</li> </ul>	Revise code 81403 by removing JAK2 test and adding Tier 1 code 8X008 for this test.
35	S-Tier 2 to Tier 1-IGH@-BCL2	<ul style="list-style-type: none"> <li>● 8X009</li> <li>▲ 81402</li> </ul>	Revise code 81402 by removing IGH@-BCL2 test and adding a Tier 1 code to report this test.
36	S-Tier 2 to Tier 1-CCND1-IGH	<ul style="list-style-type: none"> <li>● 8X010</li> <li>▲ 81401</li> </ul>	Revise code 81401 by removing IGH@-BCL2 test and adding a Tier 1 code to report this test.
37	S-GSP Epilepsy Gene Panel	<ul style="list-style-type: none"> <li>● 8X011</li> </ul>	Request to add 8X011 for reporting for epilepsy gene panel.
38	S-GSP RNA Fusion Detection-Revise 81445	<ul style="list-style-type: none"> <li>▲ 81445</li> <li>● 8X012</li> </ul>	Revise code 81445 by removing RNA testing and adding 8X012 for reporting RNA fusion of genes testing

Tab #	Name	Code #	Request-Description
39	MAAA Cutaneous Melanoma	● 815X0	Add a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code (851X0) for cutaneous melanoma recurrence risk, including likelihood of sentinel lymph node metastasis.
40	Infectious Agent Detection-Wound Pathogen	● 87XXX	Add code 87XXX to identify infectious agent detection of wound pathogens via PCR analysis.
41	Infectious Agent Detection-Urinary STI	● 87XX0	Add code 87XX0 to ID infectious agent detection of STI urinary tract.
42	Infectious Agent Detection-Nail Pathogen	● 87XX1	Add code 87XX1 to identify infectious agent detection of nail pathogens via PCR analysis.
43	Antibiotic-Resistant Gene Testing	● 87XX2	Add code 87XX2 to identify antibiotic resistant genes of bacteria.
44	PLA Code Set Maintenance	-----	Modify current PLA guidelines to add clarifying language that would determine the level of revision needed (ie a change in code number or code descriptor) based off specific elements of a test that have changed since the CPT code descriptor was published.
80	Infectious Agent Detection-Urinary Tract Pathogen	● 87XX3	Add code 87XX3 to identify infectious agent detection non-sexually transmitted urinary infections using PCR analysis.